2009. ISPOR European Congress – Impact of Tumor Response on Health-Related Quality of Life (HRQL) in Newly Diagnosed Multiple Myeloma Patients Treated with Velcade/Prednisone (V-MP): Results from the Vista Trial

Meunier J, Regnault A, Robinson D, Rosa K, San Miguel JF, van de Velde H, Richardson PG, Cakana A, Dhawan R. Impact of Tumor Response on Health-Related Quality of Life (HRQL) in Newly Diagnosed Multiple Myeloma Patients Treated with Velcade/Prednisone (V-MP): Results from the Vista Trial. Value Health. 2009 Oct;12(7):A284. Presented at: ISPOR 12th Annual European Congress; October 25, 2009; Paris, France.